We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

IBKR:NASDAQInteractive Brokers Group, Inc. Analysis

Data as of 2026-06-20 - not real-time

$96.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Interactive Brokers (IBKR) is trading at $96, comfortably above its 20‑day SMA of 87.54, 50‑day SMA of 83.48 and 200‑day SMA of 72.19, indicating a strong bullish alignment. The MACD line (3.11) sits above its signal (2.36) with a positive histogram, while the RSI is at 70.8, signaling near‑overbought conditions and suggesting a short‑term pull‑back risk. Beta of 1.90 and 30‑day volatility of 35.7% underscore heightened price swings, yet volume is trending lower, hinting at waning short‑term momentum.
Fundamentally, IBKR boasts a 16.8% revenue growth rate, a gross margin of 93%, and an operating margin of 77%, delivering a solid profit margin of 16%. The forward PE of 33.4 versus the industry average of 16.9 points to growth pricing, but the discounted cash‑flow fair value of $237.5 suggests the stock is considerably undervalued, with an upside potential well above current levels despite a modest –8% downside metric. Strong cash reserves ($124.6 B), low payout ratio (13.7%) and a sustainable dividend (0.36%) further reinforce a resilient financial profile, while recent product launches and IPO participation opportunities add to the growth narrative.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish alignment with all major SMAs
  • RSI near overbought territory
  • Decreasing volume trend indicating potential short‑term consolidation

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Significant undervaluation versus DCF fair value
  • Robust revenue and profit margin growth
  • Strategic product expansions (Agentic Trading integration, IPO access)

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Strong cash generation and low dividend payout ratio
  • Sustained high operating margins and ROE
  • Long‑term market position in capital markets with global client base

Key Metrics & Analysis

Financial Health

Revenue Growth16.80%
Profit Margin16.11%
P/E Ratio41.2
ROE23.56%
ROA2.42%
Debt/Equity152.19
P/B Ratio7.7
Op. Cash Flow$16.8B
Industry P/E16.9

Technical Analysis

TrendBullish
RSI70.8
Support$79.12
Resistance$97.81
MA 20$87.54
MA 50$83.48
MA 200$72.19
MACDBullish
VolumeDecreasing
Fear & Greed Index91.46

Valuation

Fair Value$237.49
Target Price$88.27
Upside/Downside-8.05%
GradeUndervalued
TypeGrowth
Dividend Yield0.36%

Risk Assessment

Beta1.90
Volatility35.74%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.